Evidence map›Paper›PMID 32286236›Full record

ArticleJMIR medical informatics2020

A Novel, Integrative Approach for Evaluating Progression in Multiple Sclerosis: Development of a Scoring Algorithm.

Chloe Tolley, Daniela Piani-Meier, Sarah Bentley, Bryan Bennett, Eddie Jones, James Pike, Frank Dahlke, Davorka Tomic, Tjalf Ziemssen

Abstract read
In one paragraph

Article in JMIR medical informatics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Chloe TolleyAdelphi Values Ltd, Macclesfield, United Kingdom.ORCID https://orcid.org/0000-0003-3846-9018
Daniela Piani-MeierNovartis Pharma AG, Basel, Switzerland.ORCID https://orcid.org/0000-0003-0890-9422
Sarah BentleyAdelphi Values Ltd, Macclesfield, United Kingdom.ORCID https://orcid.org/0000-0001-9914-8934
Bryan BennettAdelphi Values Ltd, Macclesfield, United Kingdom.ORCID https://orcid.org/0000-0002-5295-5576
Eddie JonesAdelphi Real World Ltd, Macclesfield, United Kingdom.ORCID https://orcid.org/0000-0002-8602-4796
James PikeAdelphi Real World Ltd, Macclesfield, United Kingdom.ORCID https://orcid.org/0000-0002-4208-2871
Frank DahlkeNovartis Pharma AG, Basel, Switzerland.ORCID https://orcid.org/0000-0003-3333-6291
Davorka TomicNovartis Pharma AG, Basel, Switzerland.ORCID https://orcid.org/0000-0002-1484-1850
Tjalf ZiemssenCenter of Clinical Neuroscience, Neurological University Clinic Carl Gustav Carus, TU Dresden, Dresden, Germany.ORCID https://orcid.org/0000-0001-8799-8202

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThere is an unmet need for a tool that helps to evaluate patients who are at risk of progressing from relapsing-remitting multiple sclerosis to secondary progressive multiple sclerosis (SPMS). A new tool supporting the evaluation of early signs suggestive of progression in multiple sclerosis (MS) has been developed. In the initial stage, concepts relevant to progression were identified using a mixed method approach involving regression on data from a real-world observational study and qualitative research with patients and physicians. The tool was drafted in a questionnaire format to assess these variables.

objectiveThis study aimed to develop the scoring algorithm for the tool, using both quantitative and qualitative research methods.

methodsThe draft scoring algorithm was developed using two approaches: quantitative analysis of real-world data and qualitative analysis based on physician interviews and ranking and weighting exercises. Variables that were included in the draft tool and regarded as most clinically relevant were selected for inclusion in a multiple logistic regression. The analyses were run using physician-reported data and patient-reported data. Subsequently, a ranking and weighting exercise was conducted with 8 experienced neurologists as part of semistructured interviews. Physicians were presented with the variables included in the draft tool and were asked to rank them in order of strength of contribution to progression and assign a weight by providing a percentage of the overall contribution. Physicians were also asked to explain their ranking and weighting choices. Concordance between physicians was explored.

resultsMultiple logistic regression identified age, MS disease activity, and Expanded Disability Status Scale score as the most significant physician-reported predictors of progression to SPMS. Patient age, mobility, and self-care were identified as the strongest patient-reported predictors of progression to SPMS. In physician interviews, the variables ranked and weighted as most important were stability or worsening of symptoms, intermittent or persistent symptoms, and presence of ambulatory and cognitive symptoms. Across all physicians, the level of concordance was 0.278 (P<.001), indicating a low to moderate, but statistically significant, level of agreement. Variables were categorized as high (n=8), moderate (n=8), or low (n=10) importance based on the findings from the different approaches described above. Accordingly, the respective questions in the tool were assigned a weight of "three," "two," or "one" to inform the draft scoring algorithm.

conclusionsThis study further confirms the need for a tool to provide a consistent, comprehensive approach across physicians to support the early evaluation of signs indicative of progression to SPMS. The novel and comprehensive approach to develop the draft scoring algorithm triangulates data obtained from ranking and weighting exercises, qualitative interviews, and a real-world observational study. Variables that go beyond the clinically most obvious impairment in lower limbs have been identified as relevant subtle/sensitive signs suggestive of progressive disease.

Indexed as

algorithmdisease progressionmultiple sclerosis, relapsing-remittingSPMStool

Identifiers

PMID32286236
PMCPMC7189255

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.